Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Retained Earnings (2017 - 2025)

Cue Biopharma's Retained Earnings history spans 9 years, with the latest figure at -$370.1 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 11.34% year-over-year to -$370.1 million; the TTM value through Sep 2025 reached -$370.1 million, down 11.34%, while the annual FY2023 figure was -$301.2 million, 20.26% down from the prior year.
  • Retained Earnings for Q3 2025 was -$370.1 million at Cue Biopharma, down from -$362.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$39000.0 in Q1 2023 and bottomed at -$370.1 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$282.3 million (2023), against an average of -$260.3 million.
  • The largest annual shift saw Retained Earnings plummeted 803841.03% in 2024 before it fell 11.34% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$189.1 million in 2021, then crashed by 32.47% to -$250.5 million in 2022, then fell by 20.26% to -$301.2 million in 2023, then dropped by 10.35% to -$332.4 million in 2024, then decreased by 11.34% to -$370.1 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Retained Earnings are -$370.1 million (Q3 2025), -$362.6 million (Q2 2025), and -$354.1 million (Q1 2025).